|
|
| MSH2 Human recombinant protein |
 |
|
|
 |
| Catalog Number: 10-663-46187 |
|
|
|
| Related Product Names:
|
-
MSH2 protein; MSH2; MSH2 Human
- MutS Homolog 2 Human Recombinant; MutS protein homolog 2; profilin-1 |
|
- Gene Information -
Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.
|
|
| Gene Name: MSH2 |
Gene Name Synonym: N/A |
Gi #:
N/A |
NCBI Acc #:
NP_000242.1 |
Swiss Prot Acc #:
P43246 |
Length (aa): N/A |
Mol. Weight (Da): 104743 |
Chrom Location: N/A |
|
|
 Presentation: Recombinant Human MSH2 protein at 100ug/ml in 50mM Tris-Acetate, pH7.5, 1mM EDTA and 20% Glycerol.
Characterization: MSH2 Antibody reactive.
Useful Applications: ELISA, Inhibition Assays, Western Blotting
Source/Host: E. Coli (Recombinant Hu MSH2 protein encoding amino acids 735-93
Shipping: Products may be shipped on ice pack or dry ice. |
|
|
|
| MSH2 PROTEIN TARGET DESCRIPTION: |
Synonym Names for MSH2 protein: MSH2; MutS Homolog 2 Human Recombinant; MutS protein homolog 2; profilin-1
MSH2 (MutS homologue 2) is a100-kDa protein involved in mismatched nucleotides during DNA replication or repair process. MSH2 functions as
one of the four major DNA mismatch repair genes along with MLH1, PMS2 and PMS1. Somatic mutations in the human MSH2 gene contribute to the development of sporadic colorectal carcinomas while germline mutations are involved in a large number of colorectal carcinoma.
Function: Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis.
Subunit: Heterodimer consisting of MSH2-MSH6 (MutS alpha) or MSH2-MSH3 (MutS beta). Both heterodimer form a ternary complex with MutL alpha (MLH1-PMS1). Interacts with EXO1. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBS1 protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts with ATR.
Subcellular Location: Nucleus (Potential).
Tissue Specificity: Ubiquitously expressed.
Ptm: Phosphorylated by PRKCZ, which may prevent MutS alpha degradation by the ubiquitin-proteasome pathway.
Ptm: Phosphorylated upon DNA damage, probably by ATM or ATR.
Disease: Defects in MSH2 are the cause of hereditary non-polyposis colorectal cancer type 1 (HNPCC1) [MIM:120435]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. MSH2 mutations may predispose to hematological malignancies and multiple cafe-au-lait spots.
Disease: Defects in MSH2 are a cause of Muir-Torre syndrome (MTS) [MIM:158320]. MTS is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.
Disease: Defects in MSH2 are a cause of susceptibility to endometrial cancer [MIM:608089].
Similarity: Belongs to the DNA mismatch repair mutS family.
OMIM: 120435; phenotype. [NCBI / EBI]
158320; phenotype. [NCBI / EBI]
608089; phenotype. [NCBI / EBI]
609309; gene. [NCBI / EBI]
Products similar to MSH2 protein:
IgG
 MSH2 (mutS homolog 2. colon cancer. nonpolyposis type 1 (E. coli)), IgG
MSH2, IgG
MSH2 [25D12], IgG
|
|
| PRODUCT INTERACTIONS: |
MSH2 Human interacts with MSH6, IgG (GenWay Catalog #: 10-663-46187).
MSH2 Human interacts with MSH6, IgG (GenWay Catalog #: 10-663-46187).
MSH2 Human interacts with Recombinant Human MutS Homolog 6, Protein (GenWay Catalog #: 10-663-46187).
MSH2 Human interacts with Protein tyrosine phosphatase type IVA protein 3, Protein (GenWay Catalog #: 10-663-46187).
MSH2 Human interacts with Recombinant Human Protein Tyrosine Phosphatase Type IVA Member 3, Protein (GenWay Catalog #: 10-663-46187).
|
|
|
SUGGESTED PROTEIN REAGENTS - GenWay offers reagents to facilitate your research with cell-based assays, Mass Spectrometry, standards, calibrators, Western blot, cell culture, antibiotics, microwell substrates, and more!
|
|
Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.
Precautions: MSH2 protein is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.
Important Notes: During shipment, small volumes of MSH2 protein vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.
Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about MSH2 protein, all related information, articles, resources about MSH2 protein are being stored on our online database. Let us know if you have questions regarding this product.
Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed. |
|
|
|
GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.
|
GenWay has a diverse line of recombinant protein expression platforms, including E. coli expression, Bacliovirus expression, yeast expression, and mammalian expression. Combining the technologies of bioinformatics, protein domain analysis, gene codon optimization, protein fusion, and protein expression in different host cells, GenWay can produce soluble and functional proteins. In particular, GenWay has the capability and vector systems for expression of difficult proteins such as proteases, kinases, glycosylated and membrane proteins. We have a very high success rate (almost 100%) and can deliver the proteins in a timely fashion. This is a core competency necessary for efficient and effective production of immunogens and affinity ligands for antibody production and purification. GenWay has over 300 recombinant proteins offered in our catalog. |
|
|
|
